Evidence map›Paper›PMID 38453449›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[A Case of Multidomain Integrated Treatment Strategy 
for Complex Primary Pulmonary Sarcomatoid Carcinoma].

Xiaosen Huo, Hang Zou, Yanyan Dong, Yuan Li, Lingjie Bian, Lei Li, Hongwu Wang

Open access · greenAbstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaosen HuoRespiratory Disease Center, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 101121, China.
Hang ZouRespiratory Disease Center, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 101121, China.
Yanyan DongRespiratory Disease Center, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 101121, China.
Yuan LiRespiratory Disease Center, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 101121, China.
Lingjie BianRespiratory Disease Center, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 101121, China.
Lei LiRespiratory Disease Center, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 101121, China.
Hongwu WangRespiratory Disease Center, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 101121, China.
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a rare and highly malignant tumor, which includes the following five pathologic types: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma and pulmonary blastoma. The onset of PSC is occult with non-specific clinical symptoms and signs. The clinical manifestations include irritating cough, bloody sputum, dyspnea, chest pain and so on, which are closely related to the growth and invasion site of the tumor. PSC tends to metastasize early, so most patients are already in local advanced stage or advanced stage with a median survival of 9 months at the time of hospital visit. A patient with primary PSC which led to 90% stenosis in central airway was treated by combined method of vascular and tracheoscopic intervention in our respiratory center. This treatment prolonged the patient's survival time and got a satisfactory effect at 19-month follow-up after surgery. Herein we report the case for clinical reference.
.

Indexed as

CarcinomaCarcinosarcomaLung NeoplasmsHumansLungPrognosisCentral airway stenosisLung neoplasmsPulmonary sarcomatoid carcinoma

Identifiers

PMID38453449
PMCPMC10918249
OpenAlexW4394768551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.